Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Teresa Amaral(University Children's Hospital Tübingen), Lisa Zimmer(The University of Sydney), Sarah Schaefer(Heidelberg University), Jochen Uttikal(German Cancer Research Center), Dirk Debus(Nuremberg Hospital), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Julia K. Tietze(LMU Klinikum), Anja Gesierich(University of Michigan), Sebastian Haferkamp(University Hospital Regensburg), David Rafei‐Shamsabadi(University Medical Center Freiburg), Claudia Pfoehler(MSH Medical School Hamburg – University of Applied Sciences and Medical University), Friedegund Meier(National Center for Tumor Diseases), Katharina C. Kaehler(Christian-Albrechts-Universität zu Kiel), Henner Stege(Johannes Gutenberg University Mainz), Thilo Gambichler(Witten/Herdecke University), Thomas Eigentler(University Children's Hospital Tübingen), Carola Berking(Universitätsklinikum Erlangen), Frank Meiß(University of Freiburg), Vanessa Heinrich, Christian Posch(Klinik Hietzing), Jessica C. Hassel(German Cancer Research Center), Lydia Reinhardt(Technische Universität Dresden), Carmen Loquai(Johannes Gutenberg University Mainz), Steffen Emmert(Universitätsmedizin Göttingen), Ante Karoglan(University Hospital Magdeburg), Felix Kiecker(Humboldt-Universität zu Berlin), Thomas Tueting(University Hospital Magdeburg), Claus Garbe(University of Tübingen), Kai Thoms(Universitätsmedizin Göttingen), Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 88
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k